4-MeO-PCP

buy 4-MeO-PCP online
4-Methoxyphencyclidine (methoxydine, 4-MeO-PCP) is a dissociative anesthetic drug that has been sold online as a research chemical. The synthesis of 4-MeO-PCP was first reported in 1965 by the Parke-Davis medicinal chemist Victor Maddox. A 1999 review published by a chemist using the pseudonym John Q.

Two years later, Beagle published a detailed description of the synthesis and qualitative effects of 4-MeO, which he said possessed 70% of the potency of PCP.

Two 4-MeO was the first arylcyclohexylamine research chemical to be sold online; it was introduced in late 2008 by a company trading under the name CBAY and was followed by several related compounds such as 3-PCP and methoxetamine. 4-MeO-PCP has lower affinity for the NMDA receptor than but higher affinity than ketamine; it is orally active in a dosage range similar to ketamine, with some users requiring doses in excess of 100 mg for desired effects.

4-MeO has values of 404 nM for the NMDA receptor, 713 nM for the norepinephrine transporter, 844 nM for the serotonin transporter, 296 nM for the σ₁ receptor and 143 nM for the σ₂ receptor

4-MeO hydrochloride is a white crystalline solid with a melting point of 181-182°C.

4-MeO has caused a fatality in combination with 4-HO-MET, venlafaxine, olanzapine, lorazepam, and hydroxyzine

On October 18, 2012, the Advisory Council on the Misuse of Drugs in the United Kingdom released a report about methoxetamine, saying that the “harms of methoxetamine are commensurate with Class B of the Misuse of Drugs Act (1971),” despite the fact that the act does not classify drugs based on harm.